2-(biphenyl-4-yloxy)-1-[(1R,2S,5S)-2-(4-methyl-1H-benzimidazol-2-yl)-3-azabicyclo[3.1.0]hex-3-yl]ethanone | 1252037-22-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(biphenyl-4-yloxy)-1-[(1R,2S,5S)-2-(4-methyl-1H-benzimidazol-2-yl)-3-azabicyclo[3.1.0]hex-3-yl]ethanone
• 英文别名: 2-(biphenyl-4-yloxy)-1-((1R,2S,5S)-2-(4-methyl-1H-benzo[d]imidazol-2-yl)-3-azabicyclo[3.1.0]hexan-3-yl)ethanone；1-[(1R,2S,5S)-2-(4-methyl-1H-benzimidazol-2-yl)-3-azabicyclo[3.1.0]hexan-3-yl]-2-(4-phenylphenoxy)ethanone
• CAS: 1252037-22-1
• 化学式: C₂₇H₂₅N₃O₂
• 分子量: 423.514
• InChiKey: FKDCHKSYYKFGDW-MZEQIWSPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  58.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-[(1R,2S,5S)-3-azabicyclo[3.1.0]hexan-2-yl]-4-methyl-1H-benzimidazole;hydrochloride 、 (4-联苯氧基)乙酸 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 2-(biphenyl-4-yloxy)-1-[(1R,2S,5S)-2-(4-methyl-1H-benzimidazol-2-yl)-3-azabicyclo[3.1.0]hex-3-yl]ethanone
  参考文献：
  名称：

  Design and Synthesis of Prolylcarboxypeptidase (PrCP) Inhibitors To Validate PrCP As A Potential Target for Obesity

  摘要：

  Prolycarboxypeptidase (PrCP) is a serine protease that may have a role in metabolism regulation. A class of reversible, potent, and selective PrCP inhibitors was developed starting from a mechanism based design for inhibiting this serine protease. Compound 8o inhibits human and mouse PrCP at IC(50) values of 1 and 2 nM and is not active (IC(50) > 25 mu M) against a panel of closely related proteases. It has lower serum binding than its close analogues and is bioavailable in mouse. Subchronic dosing of 8o in PrCP and WT mice at 100 mg/kg for 5 days resulted in a 5% reduction in body weight in WT mice and a reduction in PrCP KO mice.

  DOI：

  10.1021/jm101013m

文献信息

• Design and Synthesis of Prolylcarboxypeptidase (PrCP) Inhibitors To Validate PrCP As A Potential Target for Obesity
  作者：Changyou Zhou、Margareta Garcia-Calvo、Shirly Pinto、Matthew Lombardo、Zhe Feng、Kate Bender、KellyAnn D. Pryor、Urmi R. Bhatt、Renee M. Chabin、Wayne M. Geissler、Zhu Shen、Xinchun Tong、Zhoupeng Zhang、Kenny K. Wong、Ranabir Sinha Roy、Kevin T. Chapman、Lihu Yang、Yusheng Xiong

  DOI：10.1021/jm101013m

  日期：2010.10.14

  Prolycarboxypeptidase (PrCP) is a serine protease that may have a role in metabolism regulation. A class of reversible, potent, and selective PrCP inhibitors was developed starting from a mechanism based design for inhibiting this serine protease. Compound 8o inhibits human and mouse PrCP at IC(50) values of 1 and 2 nM and is not active (IC(50) > 25 mu M) against a panel of closely related proteases. It has lower serum binding than its close analogues and is bioavailable in mouse. Subchronic dosing of 8o in PrCP and WT mice at 100 mg/kg for 5 days resulted in a 5% reduction in body weight in WT mice and a reduction in PrCP KO mice.